Appointments

866.320.4573

Submit a Form

Questions

800.223.2273

Submit a Form

Expand Content

Research & Innovations

The physicians and scientist in the Endocrine & Metabolism Institute are committed to doing research that advances the treatment of diseases and improves the care of patients. These studies include investigations of new treatments for diabetes and other endocrine disorders, newer surgical approaches to parathyroid and thyroid conditions radiofrequency ablation of liver tumors, and surgical and medical management of obesity.

A brief description of our research projects that are actively enrolling new subjects is listed below. Should you desire any further information about our research program or interested in participating in one of our research studies, please contact:

Denise Rose
Research Coordinator
rosed2@ccf.org
216.444.8824

A phase & multicenter study designated to evaluate the efficiency & safety of a long acting hGH product in adult subjects with growth hormone deficiency

Inclusion:

  • Men and women between the ages of 23 and 70 years old
  • No r-hGH replacement therapy or use of GH secretagogues for at least 9 months with any registered or investigational r-hGH or GH secretagogue product
  • Body Mass Index (BMI, kg/m) of 23.0 to 35.0 kg/m, both inclusive

Study Contact
Andreea Mocanu
216.444.9612

FOURIER-Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects With Elevated Risk

Inclusion:

  • Age 40-86
  • History of heart attack, stroke, or symptomatic peripheral artery disease

Study Contact
Bob McCoy
216.445.4029

Metabolic Components of Osteoarthritis in Diabetes and Obesity

Inclusion:

  • Previous diagnosis of knee osteoarthritis and experiencing knee pain or stiffness
  • Obese (BMI of 30-50 kg/m2) with or without type 2 diabetes or lean (BMI of 18.5-24.9 kg/m2)

Study Contact
Mia Williams
216.444.7551

The ENDO Trial - A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Metformin and/or Sulfonylurea Anti-Diabetes Agents

Inclusion:

  • Ages between 21 and 65
  • Diagnosis of type 2 diabetes for less than 20 years
  • HbA1c greater than 7.5% and less than 10%

Exclusions: Abnormal pathologies or conditions of the gastrointestinal tract, including current ulcers of Crohn's disease, history of atresias of untreated stenoses, and current upper gastro-intestinal bleeding conditions within 3 month of randomization.

Study Contact
Andreea Mocanu
216.444.9612

Gastric Plication for the Treatment of Obesity and Related Conditions
  • 18 years old or older
  • PaBMI of < 27 with one or more significant co-morbid medical conditions
  • Ability of self-pay or pay any co-payments for the procedure and follow up

Study Contact
Chytaine Hall
216.445.3983

Somatuline® Depot (lanreotide) Injection for Acromegaly
  • Patients with Acromegaly
  • Must be treated with Somatulide┬« Depot
Post Marketing Surveillance Study of Somavert Therapy in Patients with Acromegaly
  • A pituitary imaging study performed within six months prior to start of Somavert or Acrostudy start if patient is already on Somavert treatment

Study Contact
Andreea Mocanu
216.444.9612

Exenatide Study of Cardiovascular Event Lowering Trial
  • Age 18 years or older
  • Patients with Type 2 Diabetes
  • HgbA1c 6.5% - 10% within 3 months of screening
  • Up to three oral anti-hypertension agents or insulin with up to two oral anti-hypertension agents

Study Contact
Robert McCoy
216.445.4029

The Diagnostic Accuracy of the Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and the Hypothalamic-Pituitary-Adrenal Axis (Healthy Volunteers Needed)
  • Age 18 to 80 years old
  • Study involves two Glucagon stimulation tests, one insulin tolerance test (if you are <65 years old) and one ACTH stimulation test (if you are >65 years old)
  • Stipend will be provided once testing is complete

Study Contact
Robert McCoy
216.445.4029

ACTH Stimulation Test with 25 ug Cortrosyn for Evaluation of Adult Hypothalamic Pituitary Adrenal Axis
  • Age 18 to 65 years old
  • Patients with hypothalamic pituitary adrenal disorders
  • At least three months of stable hormone replacement therapy for hormone deficiencies
  • Also seeking healthy volunteers

Study Contact
Robert McCoy
216.445.4029

Parathyroid Decrease and Artery Evaluation-Effects of Parathyroidectomy in Reducing Coronary Artery Calcification and Improving Vascular Compliance
  • 18 years or older
  • Primary or secondary hyperparathyroidism scheduled for parathyroid surgery

Study Contact
Josephine Chan
216.445.7488

Parathyroid Surgery Comparison Study-Prospective Randomized Comparison of Bilateral vs. Focal Neck Exploration for Sporadic Hyperparathyroidism
  • 18 years or older
  • Diagnosis of Sporadic Primary Hyperparathyroidism

Study Contact
Josephine Chan
216.445.7488

Schedule an Appointment Online

Call us for an Appointment

  • To find an endocrinologist or diabetes specialists for your needs, contact the Endocrinology & Metabolism Institute at 216.444.6568 (or toll-free 1.800.223.2273, ext. 46568).
  • To find a bariatric surgeon, contact the Bariatric and Metabolic Institute at 800.339.9829.

Same-day Appointments

To arrange a same-day visit, call 216.444.CARE (216.444.2273).

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.